Abstract 4130
Background
Information on outcomes after cessation of anti-PD-1 mAb for CR are scarce outside KN-001 & 006 trials. We investigated these outcomes in the French pembro EAP, where pts were less selected than in registration trials.
Methods
A multicenter ambispective cohort of advanced melanoma pts initiating pembro between May 2014-Sept 2015 (CCTIRS, #15.640) was searched for pts who achieved CR. Overall and progression-free survivals with Log rank tests were used to compare curves.
Results
687 pts (159 with brain metastases) were included from 41 centers, which covered 75% of French pembro EAP. 79 pts (13%) achieved CR, among whom 68 (10%) stopped pembro for CR. Compared with the remaining 619 pts surveyed, these 68 pts had lower baseline serum LDH levels (54.5% vs 73.8%, respectively, were normal, p = 0.016), lower ECOG PS (ECOG 0 for 298 (52.6%) and 54 (80.6%), respectively, p = 0.001), and fewer metastatic sites (p = 0.003). Of note, 10% of these 68 pts had >3 metastatic sites, 10% had brain metastases, 53% had 2010 AJCC stage M1c melanoma, and 67% had received previous treatment for advanced melanoma (mainly ipilimumab). Frequency of BRAFV600, NRAS, and c-kit mutation status was not different between pts who did or did not achieve CR. Median duration on pembro in these 68 pts was 21.2 m (range: 2.5-48.4, SD 10.0). Pembro was used alone to achieve CR in 79% of pts, while 4% received concurrent radiotherapy alone, 10% concurrent surgery alone, and 6% both treatments. At the cut-off date (13/09/2018), after a median follow-up since pembro initiation of 36.3 m and of 15.3 m since pembro cessation (2-31, SD 8.3), only 3% of pts experienced melanoma recurrence. Median recurrence-free survival was not achieved. These 2 pts received radiotherapy, with one partial response achieved. 5 pts died, with 2 deaths unrelated to melanoma (1 lymphoma, 1 chylothorax), 1 related to melanoma progression, and 2 of unknown causes.
Conclusions
In this large real-life cohort, 10% of pts reached CR and discontinued pembro. All but 3% were recurrence-free after a median 15.3 m of treatment, thus validating the discontinuation of anti-PD1 in complete responders.
Clinical trial identification
CCTIRS, #15.640.
Editorial acknowledgement
RIC-Mel network and their team.
Legal entity responsible for the study
MSD France.
Funding
MSD France.
Disclosure
P. Saiag: Honoraria (self), Advisory / Consultancy: MSD. L. Mortier: Honoraria (self), Advisory / Consultancy: MSD. C. Dutriaux: Honoraria (self), Advisory / Consultancy: MSD. L. Benmahammed: Full / Part-time employment: MSD. O. Morsli: Full / Part-time employment: MSD. C. Train: Full / Part-time employment: ClinSearch. A. Spampinato: Full / Part-time employment: MSD. M.T. Leccia: Honoraria (self), Advisory / Consultancy: MSD. N. Meyer: Advisory / Consultancy: MSD. J.J. Grob: Honoraria (self), Advisory / Consultancy: MSD.
Resources from the same session
2664 - Phase (Ph) II study of MBG453 + spartalizumab in patients (pts) with non-small cell lung cancer (NSCLC) and melanoma pretreated with anti–PD-1/L1 therapy
Presenter: Nicholas Mach
Session: Poster Display session 3
Resources:
Abstract
1285 - Preliminary results of STELLAR-001, a dose escalation phase I study of the anti-C5aR, IPH5401, in combination with durvalumab in advanced solid tumors.
Presenter: Christophe Massard
Session: Poster Display session 3
Resources:
Abstract
3808 - GOLFIG chemo-immunotherapy in metastatic colorectal cancer (mCRC) patients: A fifteen year retrospective analysis
Presenter: Pierpaolo Correale
Session: Poster Display session 3
Resources:
Abstract
5677 - Immune correlates in peripheral blood samples in a preoperative window of opportunity randomized trial of nivolumab with or without tadalafil in resectable squamous cell carcinoma of the head and neck (SCCHN)
Presenter: Larry Harshyne
Session: Poster Display session 3
Resources:
Abstract
4854 - Phase 1 evaluation of AB928, a novel dual adenosine receptor antagonist, combined with chemotherapy or AB122 (anti-PD-1) in patients (pts) with advanced malignancies
Presenter: John Powderly
Session: Poster Display session 3
Resources:
Abstract
4344 - Phase 1 Trial of CV301 in Combination with Anti-PD-1 Therapy in Non-squamous NSCLC
Presenter: Arun Rajan
Session: Poster Display session 3
Resources:
Abstract
4555 - Safety and efficacy results of the combination of DPX-Survivac, pembrolizumab and intermittent low dose cyclophosphamide (CPA) in subjects with advanced and metastatic solid tumors: preliminary results from the hepatocellular carcinoma (HCC), NSCLC, bladder cancer, & MSI-H cohorts
Presenter: Henry Conter
Session: Poster Display session 3
Resources:
Abstract
3012 - Excellent CBR and Prolonged PFS in Non-Squamous NSCLC with Oral CA-170, an Inhibitor of VISTA and PD-L1
Presenter: Vivek Radhakrishnan
Session: Poster Display session 3
Resources:
Abstract
2536 - Phase Ib/II trial of TG4001 (Tipapkinogene sovacivec), a therapeutic HPV-vaccine, and Avelumab in patients with recurrent/metastatic (R/M) HPV-16+ cancers
Presenter: Christophe Le Tourneau
Session: Poster Display session 3
Resources:
Abstract
1845 - Induction of tumor-infiltrating functional CD8 positive cells and PD-L1 expression in esophageal cancer by S-588410
Presenter: Takashi Kojima
Session: Poster Display session 3
Resources:
Abstract